Expert NetworkExpert InterviewAZN

Slingshot members are talking to an expert! The topic is:

A look into the clinical landscape for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Also reviewing the recent data from Alexion's oral factor D inhibitor, Danicopan, an add on to Ultomiris or Soliris

Executed on:Oct 13, 2022 4:30 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Dana Farber Cancer Institute
  • Professor of Medicine, Harvard Medical School & Chief Emeritus of the Stem Cell Transplant Program of the Dana-Farber/Brigham and Women's Cancer Center.
  • Treats 30 - 40 patients with cGVHD per year and 30 patients with Paroxysmal Nocturnal Hemoglobinuria each month.
  • Research focuses on Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect, aplastic anemia, and PNH.

Interview Goal

To discuss the standard of care in treating PNH and discuss the relevance of Danicopan in this space

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.